in the zone, page-12

Neo, with all due respect, biotron has to walk before it can run. You need to do phase 1 and 2 before you do phase 3 clinical trials. The more successful trials you run as you progress through the cycle, the greater the probability that you will end up with a viable drug. It's as simple as that.

For you to say that the company isn't doing the right sorts of trials is a nonsense. They are doing what is needed, step by step.

If you are saying that they don't have enough cash to support phase 3 trials, then I agree with you but that was never the plan. The company has always said that it expected that level of trialling to be conducted with an agreement from a large pharmaceutical company.